» Articles » PMID: 30356717

Early IFNγ-Mediated and Late Perforin-Mediated Suppression of Pathogenic CD4 T Cell Responses Are Both Required for Inhibition of Demyelinating Disease by CNS-Specific Autoregulatory CD8 T Cells

Overview
Journal Front Immunol
Date 2018 Oct 26
PMID 30356717
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Pathogenesis of immune-mediated demyelinating diseases like multiple sclerosis (MS) is thought to be governed by a complex cellular interplay between immunopathogenic and immunoregulatory responses. We have previously shown that central nervous system (CNS)-specific CD8 T cells have an unexpected protective role in the mouse model of MS, experimental autoimmune encephalomyelitis (EAE). In this study, we interrogated the suppressive potential of PLP178-191-specific CD8 T cells (PLP-CD8). Here, we show that PLP-CD8, when administered post-disease onset, rapidly ameliorated EAE progression, and suppressed PLP178-191-specific CD4 T cell responses as measured by delayed-type hypersensitivity (DTH). To accomplish DTH suppression, PLP-CD8 required differential production of perforin and IFNγ. Perforin was not required for the rapid suppressive action of these cells, but was critical for maintenance of optimal longer term DTH suppression. Conversely, IFNγ production by PLP-CD8 was necessary for swift DTH suppression, but was less significant for maintenance of longer term suppression. These data indicate that CNS-specific CD8 T cells employ an ordered regulatory mechanism program over a number of days during demyelinating disease and have mechanistic implications for this immunotherapeutic approach.

Citing Articles

Myelin-reactive CD8 T cells influence conventional dendritic cell subsets towards a mature and regulatory phenotype in experimental autoimmune encephalomyelitis.

Upadhye M, Wilhelm C, Rogers K, Vemulawada C, Borcherding N, Boyden A J Neuroinflammation. 2025; 22(1):54.

PMID: 40022134 PMC: 11869544. DOI: 10.1186/s12974-025-03377-8.


Disruption of IFNγ, GZMB, PRF1, or LYST Results in Reduced Suppressive Function in Human CD8+ T Cells.

Vemulawada C, Renavikar P, Crawford M, Steward-Tharp S, Karandikar N J Immunol. 2024; 212(11):1722-1732.

PMID: 38607279 PMC: 11105984. DOI: 10.4049/jimmunol.2300388.


A Functionally Distinct CXCR3/IFN-γ/IL-10 Subset Defines Disease-Suppressive Myelin-Specific CD8 T Cells.

Brate A, Boyden A, Jensen I, Badovinac V, Karandikar N J Immunol. 2021; 206(6):1151-1160.

PMID: 33558376 PMC: 8059448. DOI: 10.4049/jimmunol.2001143.


IL-12-Induced Immune Suppressive Deficit During CD8+ T-Cell Differentiation.

Renavikar P, Sinha S, Brate A, Borcherding N, Crawford M, Steward-Tharp S Front Immunol. 2020; 11:568630.

PMID: 33193343 PMC: 7657266. DOI: 10.3389/fimmu.2020.568630.


Immune Autoregulatory CD8 T Cells Require IFN-γ Responsiveness to Optimally Suppress Central Nervous System Autoimmunity.

Boyden A, Brate A, Stephens L, Karandikar N J Immunol. 2020; 205(2):359-368.

PMID: 32532836 PMC: 7343581. DOI: 10.4049/jimmunol.2000211.


References
1.
Curtsinger J, Agarwal P, Lins D, Mescher M . Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function. J Immunol. 2012; 189(2):659-68. PMC: 3392455. DOI: 10.4049/jimmunol.1102727. View

2.
Bhat P, Leggatt G, Waterhouse N, Frazer I . Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 2017; 8(6):e2836. PMC: 5520949. DOI: 10.1038/cddis.2017.67. View

3.
Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7):676-88. DOI: 10.1056/NEJMoa0706383. View

4.
Farooq S, Elkhatib W, Ashour H . The in vivo and in vitro induction of anterior chamber associated immune deviation to myelin antigens in C57BL/6 mice. Brain Behav Immun. 2014; 42:118-22. DOI: 10.1016/j.bbi.2014.06.010. View

5.
Cunnusamy K, Baughman E, Franco J, Ortega S, Sinha S, Chaudhary P . Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells. Clin Immunol. 2014; 152(1-2):115-26. PMC: 4024444. DOI: 10.1016/j.clim.2014.03.005. View